0000000000147527

AUTHOR

Sergio Cannizzaro

showing 22 related works from this author

Effects of Two Different ACE Inhibitors, Captopril and Delapril, in the Early Phases of Acute Anterior Myocardial Infarction

1999

Objective: This study was aimed at investigating the effects of captopril or delapril before and just after thrombolysis in acute anterior myocardial infarction (AMI). Patients and Methods: Study participants consisted of 89 patients, hospitalised within 4 hours of the onset of symptoms. Patients were randomly divided into two groups: the first group (45 patients, pretreatment group) received captopril 6.25mg or delapril 7.5mg orally about 15 minutes before intravenous administration of recombinant tissue plasminogen activator (rt-PA) 100mg; the second group (44 patients, late-treatment group) received captopril or delapril about 4 to 6 hours after thrombolytic treatment. Captopril/delapril…

medicine.medical_specialtyEjection fractionbiologybusiness.industrymedicine.medical_treatmentDelaprilCaptoprilGeneral MedicineThrombolysismedicine.diseaseBlood pressureHeart failureInternal medicinemedicinebiology.proteinCardiologyPharmacology (medical)Creatine kinasecardiovascular diseasesMyocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct

Effects of the Combination of Candesartan plus Captopril in Elderly Patients with Anterior Myocardial Infarction

2000

Objective: To verify the feasibility, tolerability and efficacy of the combination of captopril (75 mg/day) and candesartan (8 mg/day) in early postinfarction phases of not thrombolysed and unreperfused anterior acute myocardial infarction (AMI) in elderly patients. Design and Patients: 71 patients (aged >65 years) hospitalised for anterior AMI were randomised in a double-blind manner into two groups: group A included 35 patients who received captopril 75 mg/day within 3 days of admission plus candesartan 4mg, as a first dose, and 8 mg/day successively; group B included 36 patients who received captopril 75 mg/day and placebo. 90 days after admission, patients underwent echocardiography to …

medicine.medical_specialtyCreatinineEjection fractionbusiness.industryCaptoprilGeneral MedicinePlacebomedicine.diseaseCandesartanchemistry.chemical_compoundBlood pressurechemistryTolerabilityInternal medicineCardiologyMedicinePharmacology (medical)Myocardial infarctionbusinessmedicine.drugClinical Drug Investigation
researchProduct

Short-Term Effects of Hypertonic Saline Solution in Acute Heart Failure and Long-Term Effects of a Moderate Sodium Restriction in Patients With Compe…

2011

INTRODUCTION: Hypertonic saline solution (HSS) and a moderate Na restriction plus high furosemide dose showed beneficial effects in compensated heart failure (HF), in short and long terms. The study was aimed to verify the effects of this combination on hospitalization time, readmissions and mortality in patients in New York Heart Association (NYHA) class III. METHOD: Chronic ischemic or nonischemic cardiomyopathy uncompensated patients with HF in NYHA III functional class with ejection fraction <40%, serum creatinine <2.5 mg/dL, blood urea nitrogen <60 mg/dL and reduced urinary volume were single-blind randomized in 2 groups: the first group received a 30-minute intravenous infusion of fur…

Malemedicine.medical_specialtyHeart diseasemedicine.medical_treatmentDiuresisPatient ReadmissionFurosemideInternal medicinemedicineHumansInfusions IntravenousAgedAged 80 and overHeart FailureSaline Solution HypertonicEjection fractionbusiness.industrySodiumFurosemideGeneral MedicineDiet Sodium-RestrictedMiddle Agedmedicine.diseaseHyepertonic saline heart failure diureticsDiuresisSurgeryHospitalizationTreatment OutcomeHeart failureCirculatory systemCardiologyTonicityFemaleDiureticbusinessmedicine.drugThe American Journal of the Medical Sciences
researchProduct

Comparison of Ivabradine Versus Metoprolol in Early Phases of Reperfused Anterior Myocardial Infarction With Impaired Left Ventricular Function: Prel…

2009

BACKGROUND: beta-blockers in ST-segment elevation myocardial infarction (STEMI) are indicated for patients without a contraindication, particularly in patients with high heart rates (HR) or blood pressures. Epidemiological studies have shown that elevated HR represents a risk factor for cardiovascular morbidity. The study investigates the feasibility, tolerability, and the effects after 30 days of follow-up of ivabradine (IVA) versus metoprolol (METO) in early phases of anterior STEMI reperfused by percutaneous coronary intervention (PCI). METHODS AND RESULTS: Patients with a first anterior STEMI, Killip class I-II, an acceptable echocardiographic window, and admitted within 4hours of the o…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentMyocardial InfarctionMyocardial Reperfusion InjuryPilot ProjectsVentricular Dysfunction LeftDouble-Blind MethodInternal medicineejection fraction end systole volume ivabradinemedicineHumansIvabradinecardiovascular diseasesMyocardial infarctionAgedMetoprololKillip classEjection fractionbusiness.industryPercutaneous coronary interventionBenzazepinesMiddle Agedmedicine.diseasesurgical procedures operativeConventional PCICardiologyMyocardial infarction complicationsFemaleCardiology and Cardiovascular MedicinebusinessIvabradineFollow-Up StudiesMetoprololmedicine.drugJournal of Cardiac Failure
researchProduct

415 Does angiotensin-converting enzyme I/D polymorphism afect blood pressure and diastolic function? Findings after six years of follow up in healthy…

2003

medicine.medical_specialtyBlood pressureAngiotensin converting enzyme ibusiness.industryPolymorphism (computer science)Internal medicinemedicineHealthy subjectsCardiologyDiastolic functionCardiology and Cardiovascular MedicinebusinessEuropean Journal of Heart Failure Supplements
researchProduct

Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic f…

2004

Background Aldosterone (ALDO) exerts profibrotic effects, acting via the mineralocorticoid receptors in cardiovascular tissues. Aldosterone antagonism in combination with angiotensin-converting enzyme inhibition may better protect against the untoward effects of ALDO than angiotensin-converting enzyme inhibition alone. Methods In a double-blind randomized study, the tolerability and efficacy of canrenoate (25 mg/d) plus captopril versus captopril alone were evaluated in 510 patients with an acute anterior myocardial infarction (MI), a serum creatinine concentration 5.5 mEq/L and creatinine levels to >2.0 mg/L after 10 days of treatment were observed. At 180 days, the mitral E-wave–A-wave ra…

Malemedicine.medical_specialtyAngiotensin-Converting Enzyme Inhibitors Mineralocorticoid Receptor Antagonists/administration & dosage Myocardial Contraction/drug effects Myocardial Infarction/drug therapy Myocardial Infarction/physiopathologymedicine.drug_classMyocardial InfarctionDiastoleAngiotensin-Converting Enzyme InhibitorsPlacebochemistry.chemical_compoundDouble-Blind MethodInternal medicinemedicineHumansMineralocorticoid Receptor AntagonistsCreatinineAldosteronebiologybusiness.industryCaptoprilAngiotensin-converting enzymeMiddle AgedMyocardial ContractionchemistryTolerabilityMineralocorticoidCardiologybiology.proteinDrug Therapy CombinationFemaleCanrenoic AcidCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugAmerican Heart Journal
researchProduct

Combination of indomethacin and statin compared with indomethacin and placebo in patients with a first episode of acute pericarditis: preliminary fin…

2007

The aim of the present study was to evaluate the safety and efficacy of the combination of indomethacin and statin compared with indomethacin plus placebo in patients with a first episode of pericarditis. A total of 55 consecutive patients with acute pericarditis were randomized in a double-blind manner into two groups: group I (statin group) was treated with 150 mg of indomethacin plus 10 mg of rosuvastatin, and group 2 (placebo group) was treated with 150 mg of indomethacin plus placebo. Both groups received treatment up to the normalization of inflammation markers and for the following week. Clinical and laboratory assessments [white cell count, ESR (erythrocyte sedimentation rate) and C…

AdultMalemedicine.medical_specialtyIndomethacinPlaceboGastroenterologyElectrocardiographyPericarditisAcute pericarditisDouble-Blind MethodRecurrenceInternal medicineTroponin ImedicineHumansPericarditisRosuvastatinRosuvastatin CalciumPericarditis Colchicine Postpericardiotomy syndromeFirst episodeSulfonamidesmedicine.diagnostic_testbiologybusiness.industryAnti-Inflammatory Agents Non-SteroidalCardiovascular AgentsGeneral Medicinemedicine.diseaseSurgeryFluorobenzenesC-Reactive ProteinPyrimidinesTreatment OutcomeErythrocyte sedimentation rateAcute Diseasebiology.proteinDrug Therapy CombinationFemaleCreatine kinaseHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation MediatorsbusinessFollow-Up Studiesmedicine.drugClinical Science
researchProduct

Does angiotensin-converting enzyme gene polymorphism affect blood pressure? Findings after 6 years of follow-up in healthy subjects.

2003

Background: There has been an increase in research into the association between angiotensin-converting enzyme (ACE) gene deletion polymorphism and cardiovascular disease, with conflicting results. The present prospective long-term study was conducted to evaluate whether the DD genotype could also be associated with a higher prevalence of hypertension in healthy subjects, over 6 years of follow-up. Methods: Population: 684 healthy volunteers (aged, 25–55 years): normotensive and free of cardiovascular diseases, with acceptable echocardiographic window. All subjects had to have a normal electrocardiogram (ECG) and echocardiogram (ECHO) at entry. Study protocol: All subjects underwent a comple…

AdultMaleACE-I/D gene polymorphismmedicine.medical_specialtyTime FactorsGenotypePopulationBlood PressurePeptidyl-Dipeptidase AReference ValuesInternal medicineMedicineHumansProspective StudiesFamily historyeducationeducation.field_of_studyPolymorphism Geneticbiologybusiness.industryIncidence (epidemiology)IncidenceAngiotensin-converting enzymeVenous bloodMiddle Agedmedicine.diseaseMutagenesis InsertionalEndocrinologyBlood pressureHeart failureHypertensionbiology.proteinFemaleGene polymorphismCardiology and Cardiovascular MedicinebusinessHealthy subjectGene DeletionFollow-Up StudiesEuropean journal of heart failure
researchProduct

Combination of high bolus dose of tirofiban with half dose thrombolytics for the treatment of subacute stent thrombosis

2005

Acute stent thrombosis is rare and it is usually related to complications during the procedure. Subacute thrombosis is far more common and is associated with a high incidence of acute myocardial infarction and death. Restoration of flow by thrombolysis, emergency bypass surgery or emergency percutaneous transluminal coronary angioplasty (PTCA) has had only limited success with respect to myocardial salvage. We report the case of a patient who suffered from recurrent subacute stent thrombosis, in whom administration of tirofiban at high-dose bolus in association with a half dose of recombinant tissue plasminogen activator succeeded in restoring normal myocardial flow and stable clinical cond…

Malemedicine.medical_specialtyPercutaneous transluminal coronary angioplastymedicine.medical_treatmentMyocardial InfarctionThrombolysiCoronary AngiographyRisk AssessmentBolus (medicine)Fibrinolytic AgentsCoronary CirculationAcute thrombosiInternal medicineStentmedicineHumanscardiovascular diseasesStent thrombosisMyocardial infarctionAngioplasty Balloon CoronaryVascular PatencyAgedDose-Response Relationship Drugbusiness.industryCoronary ThrombosisGeneral MedicineTirofibanThrombolysismedicine.diseaseThrombosisSurgeryTirofibanBypass surgeryAcute DiseaseCardiologyTyrosineDrug Therapy CombinationStentsCardiology and Cardiovascular MedicinebusinessFollow-Up Studiesmedicine.drugActa Cardiologica
researchProduct

Use of bivalirudin for heparin-induced thrombocytopaenia after thrombolysis in massive pulmonary embolism: a case report

2009

A 68-year-old man was referred to the emergency department 6 h after onset of sudden acute dyspnoea. Immediate ECG showed sinus tachycardia with the typical S1-Q3-T3 pattern and incomplete right bundle branch block. The echocardiogram showed the presence of mobile thrombus in the right atrium, a distended right ventricle with free wall hypokinesia and displacement of the interventricular septum towards the left ventricle. Lung spiral computed tomography (CT) showed bilateral pulmonary involvement and confirmed the picture of a thrombotic system in the right atrium and caval vein. Thrombolytic treatment with recombinant tissue plasminogen activator (rt-PA) and heparin (alteplase 10 mg bolus,…

medicine.medical_specialtySettore MED/09 - Medicina Internamedicine.medical_treatmentCase ReportInternal medicinebivalirudin Heparin-induced thrombocytopaenia Pulmonary embolism ThrombolysismedicineBivalirudinHeparin-induced thrombocytopaeniaInterventricular septumcardiovascular diseasesThrombusLungbusiness.industryPulmonary embolismThrombolysismedicine.diseaseThrombolysisSpiral computed tomographyPulmonary embolismmedicine.anatomical_structureVentricleCardiologycardiovascular systemEmergency MedicinebusinessBivalirudinmedicine.drugInternational Journal of Emergency Medicine
researchProduct

Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently…

2008

Studies have shown that patients with compensated heart failure (HF) receiving high diuretic doses associated with normal sodium diet and fluid intake restrictions demonstrated significant reductions in readmissions and mortality compared with those who received low-sodium diets, and over a 6-month observation period, a reduction in neurohormonal activation was also observed. The aim of this study was to evaluate the effects of different sodium diets associated with different diuretic doses and different levels of fluid intake on hospital readmissions and neurohormonal changes after 6-month follow-up in patients with compensated HF. Four hundred ten consecutive patients with compensated HF …

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentchemistry.chemical_compoundElectrocardiographyInternal medicineHeart rateNatriuretic Peptide BrainReninmedicineHumansDiureticsAldosteroneAgedRetrospective StudiesHeart FailureAldosteroneEjection fractionmedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryFurosemideSodium DietaryStroke VolumeDiet Sodium-Restrictedmedicine.diseaseBlood pressureTreatment OutcomechemistryEchocardiographyHeart failureCardiologyFemaleDiureticCardiology and Cardiovascular MedicinebusinessElectrocardiographymedicine.drugFollow-Up StudiesThe American journal of cardiology
researchProduct

Is delayed facilitated percutaneous coronary intervention better than immediate in reperfused myocardial infarction? Six months follow up findings

2006

Background: There are several new strategies proposed to improve the outcome of patients with ST-elevation myocardial infarction (STEMI). One approach is the resurgent use of facilitated percutaneous coronary interventions (PCI). Until recently, deciding whether immediate PCI after combined treatment (facilitated PCI) is more appropriate than delayed PCI (short time) has not been investigated. The aim of this study, therefore, was to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI < 2 hr, and in patients initially successfully treated with pharmacological therapy and with delayed PCI (12–72 h). Methods: 451 reperfused STEMI patients, a…

Malemedicine.medical_specialtyTiclopidineTime Factorsmedicine.medical_treatmentMyocardial InfarctionFacilitated Percutaneous Coronary InterventionPlatelet Glycoprotein GPIIb-IIIa ComplexGIIb/IIIa inhibitorDelayed Percutaneous Coronary InterventionsInternal medicineAngioplastymedicineAbciximabAcute myocardial InfarctionHumanscardiovascular diseasesMyocardial infarctionAngioplasty Balloon CoronaryAgedbusiness.industryAnticoagulantsPercutaneous coronary interventionHematologyTirofibanMiddle AgedClopidogrelmedicine.diseaseCombined Modality TherapyClopidogrelsurgical procedures operativeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinesstherapeuticsCombined therapyPlatelet Aggregation InhibitorsTIMIFollow-Up Studiesmedicine.drugJournal of Thrombosis and Thrombolysis
researchProduct

Effects of captopril on myocardial protection during cardioplegia

1993

Abstract The study aimed at checking effects exerted by captopril (C) on human myocardial ACE system as well as the role played by tissue ACE inhibition in reducing reperfusion damage. A human experimental model was used during cardioplegia due to aorto-coronary-by-pass (CABG). Fifty-four patients with coronary artery disease affecting 3 vessels having suffered from acute myocardial infarction anterior (AMI-ant), homogeneous as far as ejection fraction (35–55%), number of grafts (3), clamping time, age and sex, were randomised in a double blind experiment, and were given captopril or placebo (P). A total of 4 mg/l Captopril was mixed into the cardioplegic solution with blood according to th…

Malemedicine.medical_specialtyCaptoprilEpinephrineMyocardial Reperfusion InjuryPlaceboCoronary artery diseaseNorepinephrineDouble-Blind MethodInternal medicinemedicineHumansDerivationMyocardial infarctionCoronary Artery BypassCreatine KinaseCoronary sinusEjection fractionbusiness.industryCaptoprilMiddle Agedmedicine.diseaseEpinephrineAnesthesiaHeart Arrest InducedCardiologyFemaleAngiotensin ICardiology and Cardiovascular Medicinebusinessmedicine.drugInternational Journal of Cardiology
researchProduct

Captopril does not affect plasma endothelin-1 during thrombolysis and reperfusion.

1995

Studies showed that endothelin-1 (ET-1) was increased in the acute myocardial infarction (AMI). Experimental studies reported that captopril was able to reduce ET-1 secretion, and that ET-1 was increased during reperfusion. This study was aimed to verify if captopril was able to reduce plasma ET-1 during thrombolysis in AMI. Seventy-three patients, hospitalized for suspected AMI within 4 h from the onset of symptoms suitable for thrombolysis (1st episode), Killip class 1-2, were randomized (double blind) into two groups: group 1 (37 pts), 8 F/29 M, received captopril, 6.25 mg, orally 15 min before thrombolysis. Group 2: (36 pts) 8 F/28 M, received placebo before thrombolysis. All patients m…

Malemedicine.medical_specialtyCaptoprilTime Factorsmedicine.medical_treatmentMyocardial InfarctionAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressureMyocardial ReperfusionPlaceboAnginaPlacebosElectrocardiographyDouble-Blind MethodHeart RateInternal medicineFibrinolysismedicineHumansThrombolytic TherapyMyocardial infarctionAngina UnstableCreatine KinaseKillip classbusiness.industryUnstable anginaEndothelinsCaptoprilThrombolysismedicine.diseaseRecombinant ProteinsSurgeryIsoenzymesTissue Plasminogen ActivatorCardiologyFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugInternational journal of cardiology
researchProduct

Immediate versus delayed facilitated percutaneous coronary intervention. A pilot study

2005

The study was aimed to investigate the outcomes in patients initially successfully treated pharmacologically and immediate PCI <2 hours, and in patients initially successfully treated with pharmacological therapy and delayed PCI (12-72 hours). All patients had to have successful reperfusion, to receive the combination of a standard abciximab infusion plus half dose rtPA. Similar results were observed in both groups. Delayed PCI group showed a favorable trend in restenosis and bleedings (ns) and a significant reduced angiographic evidence of thrombus formation in IRA. Our very preliminary data suggest the safety and possible use of delayed facilitated PCI in patients with STEMI. The studied …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial IschemiaEligibility DeterminationMyocardial ReperfusionPilot ProjectsAcute myocardial infarctionElectrocardiographyImmunoglobulin Fab FragmentsRestenosisInternal medicinemedicineAbciximabHumansIn patientcardiovascular diseasesThrombusAngioplasty Balloon CoronaryFacilitated pciDelayed percutaneous coronary interventionPharmacologybusiness.industryPatient SelectionPercutaneous coronary interventionAntibodies MonoclonalMiddle Agedmedicine.diseaseSurvival RateGIIb/IIIa inhibitorssurgical procedures operativeTreatment OutcomeTissue Plasminogen ActivatorConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessFacilitated percutaneous coronary interventionTIMIPlatelet Aggregation InhibitorsCombined therapymedicine.drug
researchProduct

Sensitivity, specificity and predictive value of the echocardiography and troponin-T test combination in patients with non-ST elevation acute coronar…

2004

Introduction: Patients with a negative troponin (TnT) result showed 1.4% mortality during a mean follow-up of 9–10 weeks. Mortality was greater in patients with an evidence of ischemic ECG changes and a negative TnT test (1.6–4.4%). Few studies have examined the efficacy of echocardiography (2DE) in patients with chest pain. The purpose of the present study was to determine the clinical utility, sensitivity and specificity of the combination of TnT levels and 2DE in patients presenting with chest pain, ST-depression, T-wave negative and no diagnostic ECG. Methods: 280 consecutive patients with chest pain and presence of ST depression, T-wave inversion, and non-diagnostic ECG, acceptable 2DE…

Malemedicine.medical_specialtyChest PainCoronary DiseaseChest painSensitivity and SpecificityTroponin TPredictive Value of TestsInternal medicinemedicineHumansRadiology Nuclear Medicine and imagingST depressionChi-Square Distributionbiologymedicine.diagnostic_testTroponin Tbusiness.industryST elevationMiddle Agedmusculoskeletal systemTroponinEchocardiographyPredictive value of testsAngiographyAcute Diseasebiology.proteinCardiologyFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessChi-squared distributionFollow-Up StudiesThe international journal of cardiovascular imaging
researchProduct

Safety and tolerability of abciximab in patients with acute myocardial infarction and failed thrombolysis.

2003

Abstract Aim: The aim of this study was to evaluate glycoprotein IIb/IIIa receptor inhibitor effectiveness in AMI patients with unsuccessful thrombolysis. Methods: Eighty-four patients hospitalised within 4 h of symptom onset were randomised (single blind) into two groups. Regardless of the group, placebo or GP IIb/IIIa inhibitors were administered to patients who did not present with reperfusion signs 30 min after starting thrombolysis and 30–60 min after the end of full thrombolysis in patients with pain recurrence and ST-segment elevation. Reperfusion was assessed by the creatine kinase peak occurring within 12 h, by the observation of rapid ST-segment reduction (50–70% within 1 h) in 12…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentAbciximabMyocardial InfarctionMyocardial ReperfusionPlatelet Glycoprotein GPIIb-IIIa ComplexPlaceboCoronary AngiographyAnginaElectrocardiographyImmunoglobulin Fab FragmentsInternal medicineFibrinolysisAbciximabmedicineHumansSingle-Blind MethodThrombolytic TherapyMyocardial infarctionTreatment FailureAngioplasty Balloon CoronaryAspirinbusiness.industryAntibodies MonoclonalThrombolysisMiddle Agedmedicine.diseaseTolerabilityResearch DesignAnesthesiaTissue Plasminogen ActivatorCardiologyFemaleSafetyCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drugInternational journal of cardiology
researchProduct

Thrombolysis for massive pulmonary embolism in pregnancy: a case report

2011

Adultmedicine.medical_specialtyPregnancyHeparinbusiness.industrymedicine.medical_treatmentPregnancy Complications CardiovascularGeneral MedicineThrombolysismedicine.diseasePulmonary embolismFibrinolytic AgentsPregnancyTissue Plasminogen Activatorpulmonary embolism prenancyEmergency MedicinemedicineHumansFemaleThrombolytic TherapyPulmonary EmbolismIntensive care medicinebusinessThe American Journal of Emergency Medicine
researchProduct

Effects of Administration of Glycoprotein IIb/IIIa Receptor Antagonists in Patients with Failed Thrombolysis

2001

Aim To evaluate the effectiveness of glycoprotein (GP) IIb/IIIa receptor antagonists in patients with acute myocardial infarction (AMI) who have undergone unsuccessful thrombolysis.

chemistry.chemical_classificationmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentGeneral MedicineThrombolysisTirofibanmedicine.diseaseGastroenterologyPharmacotherapychemistryInternal medicinemedicineAbciximabEptifibatidePharmacology (medical)cardiovascular diseasesMyocardial infarctionGlycoproteinbusinessReceptormedicine.drugClinical Drug Investigation
researchProduct

Relationship between ACE-DD polymorphism and diastolic performance in healthy subjects.

2004

Background—The ACE-D allele has been associated with cardiovascular disease. The study evaluates the relationship between the ACE-ID genotypes and diastolic function in healthy subjects after 6 years of follow-up. Methods—Two hundred and seventy-five healthy volunteers aged 25–55 years had normal physical examination, 12-lead ECG, acceptable echocardiographic windows and echocardiogram at entry. Venous blood was drawn for DNA analysis. Results—Two hundred and forty-two subjects completed 6 years of follow-up. Three genetically distinct groups were obtained: ACE-DD group (n=71, 26F/45M, mean age 48±7 years); ACE-ID (n=115, 39F/76M, mean age 40±7 years); and ACE-II (n=56, 20F/36M, mean age 47…

AdultMalemedicine.medical_specialtyTime FactorsGenotypeDiastolePhysical examinationPeptidyl-Dipeptidase ARisk AssessmentWhite PeopleCohort StudiesSex FactorsPolymorphism (computer science)DiastolePredictive Value of TestsReference ValuesInternal medicinemedicineHumansProspective StudiesProspective cohort studyAllelesProbabilityAnalysis of VariancePolymorphism Geneticmedicine.diagnostic_testbusiness.industryAge FactorsHemodynamicsVenous bloodMiddle AgedEchocardiography DopplerSurgeryPredictive value of testsMultivariate AnalysisCardiologyFemaleAnalysis of varianceCardiology and Cardiovascular MedicinebusinessCohort studyFollow-Up StudiesScandinavian cardiovascular journal : SCJ
researchProduct

Thrombolysis Followed by Apixaban for Massive Pulmonary Embolism and Free-floating Thrombus in Right Ventricle in a Patient with Breast Cancer

2018

Free-floating thrombus in the right ventricle, associated with a massive acute pulmonary embolism (PE), is a rare phenomenon. PE is an important clinical entity with considerable mortality despite advances in diagnosis and treatment. The prognosis of PE depends on right ventricular dysfunction, myocardial injury markers, and early treatment. In this report, we present the case of a 71-year-old woman with a history of breast cancer admitted to intensive care unit for PE complicated by syncope. Although our case may seem complex because it is not represented in the guidelines, the result was satisfactory and showed how treatment with new anticoagulants (in this case apixaban) after massive th…

thrombolysismedicine.medical_specialtymedicine.medical_treatmentCase Reportheparinright ventricle030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicineBreast cancerlawInternal medicinemedicineechocardiographyApixabanRadiology Nuclear Medicine and imaging030212 general & internal medicineThrombusbusiness.industrymassive pulmonary embolismThrombolysisHeparinmedicine.diseaseIntensive care unitPulmonary embolismmedicine.anatomical_structureVentricleCardiologyApixabanCardiology and Cardiovascular Medicinebusinessmedicine.drugJournal of Cardiovascular Echography
researchProduct

Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with hep…

2010

Abstract Introduction The aim of this study was to assess the effect of thrombolysis versus heparin treatment on echocardiographic parameters and clinical outcome, during hospitalization and within the first 180 days after admission, in patients with first episode of submassive pulmonary embolism (SPE) and right ventricle dysfunction (RVD). Methods Consecutive patients (age, 18–75 years) with a first episode of SPE, symptoms onset since no more than 6 hours, normal blood pressure (> 100 mm Hg), echocardiographic evidence of RVD and positive lung spiral computed tomography were double-blind randomized: 1 group received 100 mg of alteplase (10-mg bolus, followed by a 90-mg intravenous infusio…

Adultmedicine.medical_specialtyAdolescentmedicine.drug_classmedicine.medical_treatmentVentricular Dysfunction RightPlacebolaw.inventionYoung AdultRandomized controlled trialDouble-Blind MethodFibrinolytic AgentslawInternal medicineFibrinolysismedicineHumansThrombolytic TherapyAgedFirst episodebusiness.industryHeparinAnticoagulantpulmonary embolism echocardiographyAnticoagulantsGeneral MedicineHeparinThrombolysisMiddle Agedmedicine.diseaseSurgeryPulmonary embolismEchocardiographyTissue Plasminogen ActivatorCardiologyWarfarinbusinessPulmonary Embolismmedicine.drugThe American journal of the medical sciences
researchProduct